Dr. Scott Abrams joined the Faculty of Roswell Park Comprehensive Cancer Center (Roswell Park) in 2008 and, in 2013, was promoted to Professor of Oncology and Member in the Department of Immunology. He holds a joint appointment as Research Professor on the Graduate Faculty at the State University of New York at Buffalo. In 2014, Dr. Abrams was reappointed to the UB Graduate Faculty with Distinction. From 2013 to early 2019, he served as Director of Graduate Studies for the Immunology Graduate Program at Roswell Park during which he received two awards in graduate education and mentoring. Also, in 2018, he received the Roswell Pride in Member Ingenuity (RPMI) Award. In early 2019, Dr. Abrams was appointed as Co-Leader of the Tumor Immunology and Immunotherapy Program in the Cancer Center.
Dr. Abrams came to Roswell Park from the Laboratory of Tumor Immunology and Biology, National Cancer Institute (NCI), National Institutes of Health (NIH), in Bethesda, MD, where he served as Principal Investigator. He has been honored by the NCI/NIH with five consecutive Performance Awards from 2003–2007, and was the recipient of six NIH Federal Technology Transfer Awards for the discovery of human T lymphocyte peptide epitopes reflecting ras codon 12 mutations. The identification of such mutated ras peptide sequences has also culminated in patent approval in both Europe and the U.S.
As a tumor immunologist, his research interests focus on understanding mechanisms of tumor escape and immune suppression. Currently, Dr. Abrams serves on several external grant review panels. He has authored or co-authored more than 130 journal articles, reviews and book chapters, and has received numerous national and international invitations to speak.